The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Imugene (IMU) receives Human Research Ethics Committee (HREC) approval to start a phase two clinical trial of its cancer vaccine, HER-Vaxx in Australia
  • This approval confirms the company has completed pre-clinical safety and efficacy for the phase two trial, dubbed nextHERIZON
  • Imugene says the aim of the trial is to assess the safety and efficacy of HER-Vaxx in combination with chemotherapy or pembrolizumab in certain cancer patients
  • The company will now notify the Therapeutic Goods Administration (TGA) of its HREC approval before conducting local site initiation activities
  • Before market open, shares are trading at 16 cents each

Imugene (IMU) has received Human Research Ethics Committee (HREC) approval to start a phase two clinical trial of its cancer vaccine, HER-Vaxx in Australia.

This approval is confirmation the company has completed pre-clinical safety and efficacy in order to commence its nextHERIZON clinical trial.

This trial will assess the safety and efficacy of HER-Vaxx in combination with chemotherapy or pembrolizumab in certain cancer patients.

According to the company, the main focus is on safety and response rate, but it will also monitor duration of response, survival, and biomarker evaluation.

Imugene will now notify the Therapeutic Goods Administration (TGA) of its HREC approval before conducting local site initiation activities.

Two Australian hospitals have received ethics approval, with additional sites to be opened in Australia and the US.

“The start of our Australian study is a significant milestone for Imugene and clinicians treating Australians faced with the challenge of HER-2+ gastric cancer and we look forward to further evaluating HER-Vaxx in combination with pembrolizumab in a relapsed/refractory metastatic setting,” Managing Director and CEO Leslie Chong said.

Before the market opens for the day, IMU shares were trading at 16 cents each on May 9.

imu by the numbers
More From The Market Online

Market Close: ASX slides 1.58% as global AI sell-off rattles investors

My nerves, along with my portfolio, have taken a beating over the last couple of weeks – and I’m sick of seeing red!

Market Close: Materials drag ASX lower as seven sectors finish higher

The Australian share market finished lower on Monday, with weakness across the resources sector weighing on the broader market despite gains across most

Market Close: ASX slides as resources and miners lead broad market sell-off

The Australian sharemarket came under renewed pressure on Tuesday 17th Nov, with selling extending across almost every sector as resources and energy

Market Close: ASX slides as technology and materials stocks lead broad market decline

The Australian share market finished lower on Wednesday, with the S&P/ASX 200 falling 0.69% to close at 8,821.80 points.